Pfizer receives warning letter over EpiPen manufacturing; Opdivo kidney-cancer trial shows improved survival rates; cancer patients who discuss costs with physicians pay less
The FDA halts IO-combo trial for Opdivo; Lilly slashes 3,500 jobs; new asthma drug could treat wide range of patients
The FDA warns drugmaker over opioid promotion; Watson may not be living up to the hype; Merck acquires immuno-oncology biotech
The FDA suspends three Keytruda studies; drug and device makers gave $8 billion in payments to providers in 2016; Opdivo beat Yervoy in skin-cancer trial
Jim Caggiano had witnessed Provenge's birth during an earlier turn at Dendreon and couldn't understand what went wrong.
Sales of Merck's Keytruda double in the first quarter; the FDA approves AstraZeneca's immunotherapy; Lilly's insulin is under investigation in two states
Ads promoting Merck's and Bristol-Myers Squibb's immunotherapies could signal the beginning of a new era for DTC.
Thirty-percent of Keytruda's U.S. sales came from its lung-cancer indication.
Merck said the FDA accepted its submission of a Keytruda/chemotherapy combo drug and granted it Priority Review.
The FDA accepts Keytruda combo for review; Valeant offloads Dendreon and skincare brands; pharmacies feeling the squeeze from Express Scripts
On the heels of Keytruda's approval in first-line lung cancer, the drugmaker kicked off an unbranded campaign raising awareness about biomarkers.
Keytruda is the first immuno-oncology drug approved to treat first-line lung cancer.
Merck launches biosimilar resource; branded insulin prices are on the rise; NICE declines to cover Opdivo
Already ahead in race to first-line approval, could second-line domination be far behind for Keytruda?September 09, 2016
One analyst envisions how a first-line approval could set up Keytruda for success in other settings.
Critics say the direct-to-consumer ad for the immuno-oncology therapy is misleading.
Sales of Gilead's HCV drugs fall; the DNC policy platform criticized price gouging; Janssen partners with Bristol-Myers Squibb on Opdivo combo drug
FDA leader says drugmakers should develop more novel drugs; Merck to acquire Afferent for $1.25 billion; Colombia demands lower prices for Gleevec
Here, see side-by-side comparisons of the drugs spending on advertising, approval dates, and 2015 sales figures.
Immuno-oncology drugs showing results in hard-to-treat cancers; Express Scripts responds to Anthem lawsuit; BI and Lilly plan outcomes trials for Jardiance
Bristol-Myers Squibb seeks new indication for Opdivo; Clinton received $2.8 million from the healthcare industry; Quest creates tests for hep.-C drugs
Manufacturers team up to study drug combinations, a strategy expected to advance the category.
Cancer MoonShot 2020 to study childhood cancers; IBM's purchase of Truven provides data about 200 million patients; overdoses tied to benzodiazepines rise
Shire buys Baxalta, creates world's largest rare-disease drugmaker; drug prices continue to climb; immunotherapy coalition is formed
Britain says Bristol-Myers Squibb's Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials
Opdivo receives another indication; increasing generic prescriptions may boost patient adherence; hep.-C drugs should be prescribed during earlier stages of disease
The FDA approves Opdivo/Yervoy combination to treat melanoma; BioMarin acquires global rights to Kuvan; Allergan's Juvederm receives marketing approval for lip augmentation
The drugmaker launched its first YouTube channel as it kicked off the campaign.
The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision
The immuno-oncology drug is competing with Bristol-Myers Squibb's Opdivo.
Sanofi plans immuno-oncology collaboration with Regeneron; Merck considers hard-to-treat patient populations for its experimental hepatitis-C therapy; drugmakers did not report 10% of adverse events to the FDA within required timeframe